← Back to Search

PsA Screening Questionnaire for Psoriatic Arthritis

N/A

Recruiting

Led By Jessica Walsh, M.D.

Research Sponsored by Jessica Walsh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be age 18 or older

Have an International Classification of Diseases (ICD) code diagnosis of psoriasis but without a confirmed diagnosis of Psoriatic Arthritis prior to study initiation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will aim to develop a screening questionnaire that can be used by psoriasis patients to detect early signs of Psoriatic Arthritis, without needing to involve dermatologists.

Who is the study for?

This trial is for adults over 18 with a diagnosis of psoriasis who haven't been diagnosed with Psoriatic Arthritis. Participants should live close to the study site and have not started any treatment for Psoriatic Arthritis.Check my eligibility

What is being tested?

The study is testing a new way to find out if people with psoriasis might also have Psoriatic Arthritis using a questionnaire that patients can fill out on their own, without needing to visit doctors' offices.See study design

What are the potential side effects?

Since this trial involves completing a questionnaire rather than taking medication or undergoing medical procedures, there are no direct physical side effects associated with participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with psoriasis but not with psoriatic arthritis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of patients with a new PsA diagnosis

Symptom duration

Secondary outcome measures

Percentage of patients who complete a rheumatologic evaluation

Physical function level in PsA

PsA Activity by Dactilitis Count

+6 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Intervention with Standard of Care ReferralExperimental Treatment1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist

Group II: Intervention with Direct Access to RheumatologistExperimental Treatment1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation

Group III: ControlActive Control1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jessica WalshLead Sponsor

Jessica Walsh, M.D.Principal Investigator - University of Utah

U-U Pulmonary Division, University Of Utah Adult Services, VA Salt Lake City Health Care System

University Of Utah School Of Medicine (Medical School)

University Of Ut Medical Center (Residency)

Media Library

Direct to patient PsA Screening Questionnaire Clinical Trial Eligibility Overview. Trial Name: NCT04110522 — N/A

Direct to patient PsA Screening Questionnaire 2023 Treatment Timeline for Medical Study. Trial Name: NCT04110522 — N/A

Psoriatic Arthritis Research Study Groups: Control, Intervention with Standard of Care Referral, Intervention with Direct Access to Rheumatologist

Psoriatic Arthritis Clinical Trial 2023: Direct to patient PsA Screening Questionnaire Highlights & Side Effects. Trial Name: NCT04110522 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ultimate goal of this clinical research?

"As the primary outcome variable, this medical study will measure symptom duration over a six-month period. Secondary outcomes for evaluation include percentage of psoriasis patients who complete a rheumatologic evaluation between experimental arms and control arm; time to initial PsA diagnosis after questionnaire dissemination in the direct access to rheumatologist intervention compared with standard of care referral; and time to rheumatologic evaluation after questionnaire dissemination between those two interventions."

Answered by AI

What is the current participant count of this research endeavor?

"Affirmative. According to clinicaltrials.gov, the study is presently accepting volunteers and was updated recently on January 3rd 2022. 18000 participants are being sought from two medical locations as initially posted back in July 22nd 2019."

Answered by AI

Are there still openings in this research project to join?

"That is accurate. According to the clinicaltrials.gov record, this research project was initiated on July 22nd 2019 and recently updated on January 3rd 2022. The study aims to enrol eighteen thousand participants from two different medical sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Psoriatic Arthritis D2P Screening

Jessica Walsh 2019. "Psoriatic Arthritis D2P Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04110522.

All > Psoriatic Arthritis